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Abstract Bradykinin (BK) is a member of the kinin
family, released in response to inflammation, trauma,
burns, shock, allergy and some cardiovascular diseases,
provoking vasodilatation and increased vascular perme-
ability among other effects. Their actions are mediated
through at least two G-protein coupled receptors, B1 a
receptor up-regulated during inflammation episodes or
tissue trauma and B2 that is constitutively expressed in a
variety of cell types. The goal of the present work is to
carry out a structure–activity study of BK B2 antagonism,
taking into account the stereochemical features of diverse
non-peptide antagonists and the way these features trans-
late into ligand anchoring points to complementary regions
of the receptor, through the analysis of the respective
ligand-receptor complex. For this purpose an atomistic
model of the BK B2 receptor was built by homology
modeling and subsequently refined embedded in a lipid
bilayer by means of a 600 ns molecular dynamics trajec-
tory. The average structure from the last hundred
nanoseconds of the molecular dynamics trajectory was
energy minimized and used as model of the receptor for
docking studies. For this purpose, a set of compounds with
antagonistic profile, covering maximal diversity were
selected from the literature. Specifically, the set of com-
pounds include Fasitibant, FR173657, Anatibant,
WIN64338, Bradyzide, CHEMBL442294, and JSM10292.
Molecules were docked into the BK B2 receptor model and
the corresponding complexes analyzed to understand
ligand-receptor interactions. The outcome of this study is
summarized in a 3D pharmacophore that explains the
observed structure–activity results and provides insight into
the design of novel molecules with antagonistic profile. To
prove the validity of the pharmacophore hypothesized a
virtual screening process was also carried out. The phar-
macophore was used as query to identify new hits using
diverse databases of molecules. The results of this study
revealed a set of new hits with structures not connected to
the molecules used for pharmacophore development. A few
of these structures were purchased and tested. The results
of the binding studies show about a 33 % success rate with
a correlation between the number of pharmacophore points
fulfilled and their antagonistic potency. Some of these
structures are disclosed in the present work.
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Introduction
Kinins are a group of peptides ubiquitously produced by
the action of kallikreins on circulating kininogens in
response to inflammation, trauma, burns, shock, allergy and
some cardiovascular diseases, provoking changes in blood
pressure and vasodilation, increased vascular permeability,
stimulation of sensory neurons, vascular and bronchial
smooth muscle contraction, intestinal ion secretion, release
of prostaglandins and cytokines, and the production of
nitric oxide [1, 2]. Peptides of this group include brady-
kinin (BK), with sequence Arg1–Pro2–Pro3–Gly4–Phe5–
Ser6–Pro7–Phe8–Arg9; the closely related kallidin (Lys-
BK) and the metabolites of both, desArg9-BK and Lys-
desArg9-BK. The pharmacological actions of kinins are
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mediated by at least two G-protein coupled receptors: B1
and B2. The former is up-regulated during inflammation
episodes or tissue trauma whereas, the latter is constitu-
tively expressed in a variety of cell types. Members of the
kinin family bind to these receptors with diverse affinity.
Thus, BK and Lys-BK exhibit much higher affinity to the
B2 receptor, whereas the desArg
9 metabolites bind only to
the B1 receptor, being Lys-desArg
9 a potent B1 agonist.
Due to their role in mediating pain and inflammation there
has been a remarkable interest for identifying potent kinin
antagonists for therapeutical intervention in the last years
[3, 4].
Since the chemical synthesis of BK for the first time in
the early 60 s [5] diverse analogs with agonistic activity
have been reported, providing key information about the
relevance of every residue for ligand activity. Analogs with
antagonistic activity were not available until 1985, when
Stewart and Vavrek replaced Pro7 by an aromatic D-amino
acid [6]. This led to the first generation of antagonists with
the synthesis of potent analogs, including D-Arg-[Hyp3,
D-Phe7]-BK (NPC-567) (Hyp = hydroxyproline); D-Arg-
[Hyp3, Thi5,8, D-Phe7]-BK (NPC-349) (Thi = thienylala-
nine); or D-Arg-[Hyp3, D-Phe7, Leu8]-BK, among the most
active compounds reported [7, 8]. Although this first gen-
eration of antagonists was useful to understand the
involvement of BK in many pathophysiological processes,
these compounds exhibit drawbacks that prevent them to
be used for therapeutical intervention. Specifically, they
exhibit low affinity for the B2 receptor compared to BK
itself and are not selective, showing higher affinity for B2.
Interestingly, removal of their C-terminal arginine by car-
boxypeptidases results in a decrease of affinity for the B2
receptor, turning them selective B1 antagonists.
A second generation of antagonists with improved
pharmacological profile was designed on the basis that the
C-terminus of BK adopts a b-turn when bound to the
receptor, as had been suggested from spectroscopic and
molecular modeling studies [9] and confirmed more
recently, in solid state NMR experiments [10]. Thus, with
the help of conformationally constrained unnatural amino
acids, diverse analogs designed to mimic the secondary
structural motif of BK at the C-terminus were synthesized.
These studies resulted in the discovery of several potent
antagonists, including icatibant (formerly known as HOE-
140) with sequence D-Arg0-[Hyp3, Thi5, D-Tic7, Oic8]-BK
(Tic = tetrahydroisoquinoline; Oic = octahydroindole
carboxylic acid) [11] or NPC17731 (D-Arg-[Hyp3,
D-HypE(trans-proyl)7, Oic8]-BK) [12]. In a parallel effort,
the search for the shortest peptide sequence retaining
antagonistic activity led to conclude that adoption of a b-
turn conformation at the C-terminus is a necessary condi-
tion for high affinity to the B2 receptor, but not sufficient.
This conclusion came from the analysis of the binding
affinity of diverse cyclic peptides inspired on the C-ter-
minus of icatibant. Thus for example compounds like the
cyclo-(Gly-Thi-D-Tic-Oic-Arg) [13] or cyclo-(Pro-Orn-D-
Tic-Oic-Arg) [14] show poor antagonistic affinity for the
B2 receptor. Accordingly, the affinity of icatibant and
analogs was rationalized in terms of the interactions of the
compound with the receptor, such that the b-turn at the
C-terminus was thought to occupy a hydrophobic region on
the orthosteric pocket, whereas the N-terminal arginine
were thought to interact with the negatively charged resi-
dues Asp266 and Asp284, putatively located at the mouth of
the receptor [15]. As an indirect proof of concept, the high
affinity peptide D-Arg0-Arg1-Pro2-Hyp3-Gly4-Thi5-cy-
clo[Dab6-D-Tic7-Oic8-Arg9] (Dab = diaminobutyric acid)
(MEN11270) exhibits a cyclic structure at the C-terminus
mimicking the b-turn secondary structure and preserves the
N-terminal segment of icatibant [16].
The second generation of B2 antagonists represented an
improvement in regard to the first one. Thus, in addition to
have designed antagonists with high affinity for the B2
receptor, these compounds are highly selective and exhibit
an improved pharmacokinetic profile due to their higher
resistance to enzymatic degradation. However, they exhibit
a limited oral bioavailability. Thus icatibant, the first B2
antagonist to reach the market and currently used for the
symptomatic treatment of acute attacks of hereditary
angioedema in adults with C1-esterase-inhibitor deficiency,
needs to be administered via subcutaneous injection [17].
In order to improve the oral bioavailability, research efforts
were put forward to design non-peptide B2 selective
antagonists. This third generation of BK B2 antagonists
includes diverse molecules disclosed during the 90 s and
the beginning of the twenty-first century [18, 19]. Specif-
ically, WIN64338 developed at Sterling Winthrop was the
first BK B2 non-peptide antagonist disclosed (4 in Fig. 1)
[20]. Other compounds were disclosed in the following
years, including a series of compounds developed by
Fujisawa, like FR173657 (2 in Fig. 1) [21]; bradyzide
developed by Novartis (5 in Fig. 1) [22]; anatibant devel-
oped by Fournier (3 in Fig. 1) [23] or fasitibant developed
by Menarini (1 in Fig. 1) [24]. These compounds are high
affinity BK B2 selective antagonists with limited oral
bioavailability. The drawback of these compounds regards
their high molecular mass, ranging between 500 and 600.
Aimed at finding compounds with lower molecular mass,
scientists at Jerini carried out a medicinal chemistry opti-
mization process, using the 8-benzyloxy-2-methyl-quino-
line moiety, that is the common scaffold of several of the
non-peptide antagonists listed above, as starting structure.
Their study led to the design and synthesis of JSM10292 a
potent B2 antagonist with similar affinity and selectivity to
the previous compounds, but with lower molecular mass
[25].
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Fig. 1 Chemical structures of the B2 antagonists studied in the present work. Fasitibant (1), FR173657 (2), Anatibant (3); WIN64338 (4);
Bradyzide (5); CHEMBL442294 (6); JSM10292 (7)
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The goal of the present work is to carry out a structure–
activity study of BK B2 antagonism, taking into account the
stereochemical features of diverse non-peptide antagonists
and the way these features translate into ligand anchoring
points to complementary regions of the receptor, through
the analysis of the respective ligand-receptor complex. For
this purpose we selected a set of compounds from the lit-
erature covering maximal diversity. The compounds
selected for the present study include Fasitibant (1) [24],
FR173657 (2) [21], Anatibant (3) [23], WIN64338 (4) [20],
Bradyzide (5) [22], CHEMBL442294 (6) [25], and
JSM10292 (7) [26], shown in Fig. 1. Compounds were
docked into a refined model of the BK B2 receptor con-
structed by homology modeling, following the procedure
explained in the methods section, and the complexes were
further analyzed for their ligand-receptor interactions. The
outcome of this study is summarized on a 3D pharma-
cophore that explains the observed structure–activity
results and provides insight into the design of novel
molecules with antagonistic profile.
Methods
Computational methods
A starting model of the human BK B2 receptor was con-
structed by homology modeling using the chemokine
CXCR4 receptor as template (pdb entry code 3ODU) [27].
The template was selected due to its proximity to BK B2 in
the GPCRs phylogenetic tree among those GPCRs whose
crystallographic structure is known. The sequences of the
two receptors were aligned, taking into account the con-
served motifs found in all GPCRs, as well as the location of
the disulfide bridges. These motifs, together with salt
bridges are important factors in constraining the confor-
mation of the extracellular and transmembrane domains of
the B2 receptor. From the aligned sequences a starting
model of the receptor was constructed using the Modeller 9
version 8 (9v8) software [28]. Model validation was carried
out using the Molecular operating Environment (MOE)
program [29]. In a subsequent step the B2 antagonist fasi-
tibant (compound 7 in Fig. 1) was docked into the
orthosteric site of the starting model using the GLIDE
software [30]. The choice of this ligand was due to the
abundant information available from site directed muta-
genesis experiments [31]. Finally, the ligand-receptor
complex was embedded in a lipid bilayer and refined using
molecular dynamics. Specifically, the protein was embed-
ded in a box consisting in a 1-palmitoyl-2-oleoyl-sn-glyc-
ero-3-phosphocholine (POPC) lipids and water molecules
previously equilibrated according to the procedure descri-
bed elsewhere [32]. The box had an initial size of
10.3 9 8.0 9 10.2 nm3 (XYZ), organized in such a way
that the bilayer plane was oriented on the XY plane. Before
protein insertion, the box contained 256 lipids (corre-
sponding to an area per lipid of 0.64 nm2) and circa 17,000
water molecules. The protein was placed in the center of
the box, and the overlapping molecules were removed.
More specifically, all water molecules with oxygen atoms
closer than 0.40 nm to a non-hydrogen atom of the protein,
as well as all lipid molecules with at least one atom closer
than 0.25 nm to a non-hydrogen atom of the protein were
removed. This resulted in a final box containing 197 lipids
and circa 16,000 water molecules. Removal of these atoms
introduced small voids between the protein and water or
lipid molecules that disappeared during the first part of the
MD simulation, in which a progressive adjustment of the
lipid bilayer and water molecules to the protein takes place.
Next, 114 randomly selected water molecules were
replaced by 58 sodium and 56 chloride ions, providing a
neutral system with a concentration approximately 0.2 M
on sodium chloride. This concentration is fairly similar to
that found in biological organisms, although they exhibit
different intra- and extra-cellular ion concentrations.
Sampling was carried out for 600 ns using the OPLS-
AA force field with the GROMACS package 4.6 [33]. The
refined model of the BK B2 receptor was generated from
the average structure of the last 100 ns of the molecular
dynamics trajectory. The structure was subsequently min-
imized in a two-step process using the steepest descent
method with a dielectric constant of 2. First, side chains are
optimized with the backbone atoms constrained to be
subsequently released in a second minimization. This
structure was used for further docking studies using the
GLIDE [30] software. Docking was carried out with a rigid
receptor and with the ligand free to move. However due to
the flexibility of the ligands several docking attempts were
carried out using a set of unique conformations resulted
from a previous thorough conformational analysis of the
ligands. Poses were rank ordered using the XP scoring
function of GLIDE. Final poses of the compounds were
decided based on their ranking and fulfillment of site
directed mutagenesis information available. Final poses
were energy minimized using the steepest decent method
with a dielectric constant of 2, using the OPLS-AA force
field [33] to get a full relaxation of the ligand-receptor
complexes.
Binding assays
B2 antagonism assays were carried out following a protocol
described elsewhere [34]. Specifically, compounds were
tested on human recombinant bradykinin B2 receptors
expressed in CHO cells. Saturation isotherms were
obtained with [3H]-bradykinin (0.2 nM) incubated for
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60 min at room temperature. Non-specific binding was
evaluated by adding bradykinin at 1 lM. Antagonism of
unlabeled compounds was measured as the percentage of
inhibition of the binding of [3H]-bradykinin at one con-
centration using NPC-567 as reference compound.
Results and discussion
Although the number of crystallographic structures of
GPCRs available has increased steadily during the last few
years, there are still challenges that hamper the availability
of new ones, including their low-expression yields, low
receptor stability after detergent extraction from native
membranes, and high conformational heterogeneity. In the
absence of a crystallographic structure of the BK B2
receptor we proceeded to construct an atomistic model by
homology modelling for the present study. Under these
circumstances homology modeling remains one of the
important techniques aimed at constructing 3D models of
proteins, however in order for the models constructed to be
as accurate as possible the procedure requires a careful
choice of the template and a robust refinement procedure.
This is important because from the analysis of the diverse
known structures, although they share a common seven
helix bundle, each structure exhibits specific features that
might be relevant for ligand design [35]. The CXCR4
chemokine receptor (pdb entry code 3ODU) [27] was
selected as template for the present study due to its prox-
imity with BK B2 in the phylogenetic tree of the class A
family of GPCRs.
Figure 2 shows the alignment of the sequences of the
CXCR4 and BK B2 receptors carried out taking into
account the conserved motifs found among GPCRs, as
explained in the methods section. This procedure is crucial
for the assignment of the transmembrane regions. This
information is then given as input to the Modeller software
that produces a rank order set of models based on a scoring
function. The final model selected for the refinement pro-
cess was the one with the least steric conflicts from those
that incorporated all the specified constraints considered to
be conserved among GPCRs.
Before proceeding to the refinement process, fasitibant
was docked into the initial model. Due to its flexible
structure several docking attempts were carried out using
diverse conformations that were generated automatically as
explained in the methods section. The final complex con-
sidered for refinement was selected based on the degree of
fulfilment of diverse site-directed mutagenesis studies.
Special attention was given to residues Trp86, Ile110,
Trp256, Asp266 and Tyr295 [31].
The complex fasitibant bound-receptor was embedded
into a pre-equilibrated bilayer of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and water and subjected
to a molecular dynamics simulation. Previous experience in
GPCR homology modeling (data not shown), suggest that
the presence of the ligand permits a faster equilibration of
the system. Time evolution of the root mean square devi-
ation (rmsd) of the alpha carbons of the protein, as well as
those of its helical bundle subset is show in Fig. 3.
Inspection of the Figure indicates that when all the alpha
carbons of the protein are considered equilibration is
reached after 300 ns, whereas when the helical bundle
subset is used equilibration is reached about 50 ns earlier.
These results support the choice made in the present work
of using the last 100 ns of the refinement process for the
generation of an atomistic model of the BK B2 receptor. As
mentioned in the methods section, the last 100 ns segment
of the molecular dynamics trajectory was used to generate
an average structure that was subsequently minimized in a
two-step process using the steepest descent method with a
distance dependent dielectric constant of 2. The orthosteric
site of the BK B2 receptor can be described as two
hydrophobic pockets, a lager one formed between TM3,
TM4, TM5 and TM6 including residues like Ile110, Met165,
Leu201, Trp256, Phe259 and a smaller one formed between
TM2, TM3 and TM7 including residues like Trp86 and
Tyr295. Interestingly, the aromatic side chains Trp86, Trp256
and Tyr295 are coupled through quadrupole–quadrupole
interactions. On the other hand, at the mouth of the site
there are several polar residues including, Glu24, Gln33,
Asp266, Asp284 and Gln288. Figure 4 shows the orthosteric
pocket of the receptor. Below, we describe the bound
conformation of the diverse antagonists used in this study
obtained from docking studies on the refined model.
Fasitibant
Fasitibant (MEN16132) (1, in Fig. 1) is a potent antagonist
of the BK B2 receptor with a Ki of 0.09 nM [31]. The
structure of fasitibant bound to the model receptor from the
present docking study is shown in Fig. 5. In accordance
with previous docking studies [31], the quaternary terminal
amine interacts with Asp266 and Asp284 at the mouth of the
receptor, whereas the hydrophobic 8-benzyloxy-2-methyl-
quinoline moiety gets deep into the orthosteric pocket. The
involvement of the two aspartates in ligand binding is
supported by site-directed mutagenesis analysis [36].
Inspection of Fig. 5 shows the tetrahydropyranyl moiety
sitting in a hydrophobic region on top of Trp86, with the
heterocycle oxygen and the hydrogen of the indole nitrogen
of the tryptophan side chain close enough to exhibit a polar
interaction. This result is consistent with the fact that
binding of fasitibant to the Trp86Ala mutant is about 1200
times lower [31] and can be explained on the basis that the
quadrupole–quadrupole interaction between the two rings
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Fig. 2 Sequence alignment of
human BK B2 (bottom) and
CXC4 receptors.
Transmembrane segments are
inserted in boxes and sequence
identities are colored in blue
Fig. 3 Time evolution of the
root mean square deviation
(rmsd) of the bradykinin B2
receptor during the refinement
process. In black is the rmsd of
the alpha carbons of the protein
and in red the rmsd of the alpha
carbons of the helix bundle
subset
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and a hydrogen bond are lost in the mutant. Analyzing
other functional groups of the ligand, one of the oxygens of
the sulfonamide appears forming a hydrogen bond with
Arg169; one of the chlorines of the dichlorobenzyloxy
moiety forms a polar interaction with Arg169 and Asn107,
whereas the other sits in a hydrophobic environment
flanked by Phe259, Phe292 and possibly with Tyr295.
Unfortunately, there is no mutagenesis data available about
the involvement of Arg169 or Phe259 in the affinity of the
ligand to give support to these interactions. At the molecule
ending, the quinoline moiety sits in the vicinity of Ile110,
Trp256 and Tyr295 interacting with the latter two through
quadrupole–quadrupole interactions. Moreover, the inter-
action with Tyr295 is enhanced by the presence of a
hydrogen bond between the quinoline amine group of the
ligand and the hydroxyl group of Tyr295. These results are
Fig. 4 (A) Lateral view of the
orthosteric binding pocket of the
human BK B2 receptor with
fasitibant bound; (B) Same as
(A) viewed from the
extracellular side (top)
Fig. 5 Pictorial view of the
proposed binding mode of
fasitibant to the BK B2 receptor
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consistent with diverse site directed mutagenesis data
available. Thus, the mutant Ile110Ala reduces 300 times the
affinity of fasitibant and furthermore, the mutation
Tyr295Phe reduces the affinity 100 times, whereas the
mutation Tyr295Ala 755 times, suggesting a dual role as
aromatic/hydrophobic residue and as hydrogen bond donor/
acceptor for Tyr295 [31].
FRI73657
This Fujisawa compound (2 in Fig. 1) is a potent B2
antagonist with an IC50 of 1.4 nM at the human receptor
[21]. This compound is the result of an extensive medicinal
chemistry program aimed at designing B2 selective antag-
onists from a hit found in a screening program for angio-
tensin II AT1 antagonists. As can be seen the compound
shares with fasitibant the 8-benzyloxy-2-methyl-quinoline
moiety and consequently, it could be thought that the
compound binds in a similar manner, however site-directed
mutagenesis studies suggest that the bound conformation is
different. Thus, for example the affinity of FR173657 is not
affected by the mutation of Asp266 and Asp284 [36] or
Ser111 and Trp256 [37], suggesting that these residues do
not act as anchoring points in the bound conformation of
the compound. In contrast, Trp86 and Tyr295 must be
actively involved since their mutation to alanine decreases
the affinity of the compound about 500 times [31]. Bearing
these results in mind, several docking attempts were carried
out, obtaining diverse alternative poses. Analysis of the
results in view of the site-directed mutagenesis results
available suggests that the ligand binds according to the
ligand-receptor complex shown in Fig. 6. Specifically, the
molecule adopts a L-shape with the dichlorobenzyloxyl
moiety found on top of Trp86, nicely interacting through a
parallel p–p stacking in such a way that both chlorines in
addition to sit in a hydrophobic environment, interact
through a hydrogen bond with Asn107 and Gln288, respec-
tively. Unfortunately, there are not mutagenesis results of
the role of these two residues, but structure activity studies
of different analogs of FR173657 suggest that replacing the
chlorines for methyl groups decreases the affinity about
five times, supporting the existence of the hydrogen bond
interaction [38]. The position of the dichlorobenzyloxyl
permits to direct the quinoline moiety -similar as it is found
in fasitibant- in the vicinity of residues Ile110 and Phe256
whose mutation is known to affect significantly ligand
binding. An additional piece of information to support the
position of the quinoline moiety comes from a CoMFA
analysis described in reference 36. Specifically, the authors
proposed constraints for favorable groups to improve the
affinity of the ligand by extension of the molecule and
these fit well with the positions of residues Trp256, Phe259
and Asn198 in the present ligand-receptor complex. On the
other side of the molecule, structure activity studies of
diverse analogs suggest the importance of this part of the
molecule for obtaining good antagonists at the human BK
B2 receptor. Analysis of ligand-receptor complex shown in
Fig. 6 suggests that the amide groups interact with polar
residues like Glu24 or Thr89 whereas the pyridine ring
interacts with Phe94 and Tyr174 through quadrupole–
quadrupole interactions. These results agree well with the
structure–activity studies carried out on these compound
series. Specifically, the introduction of a phenylurea moiety
induces an increase in the affinity one order of magnitude
in guinea pig ileum membrane preparations and nearly two
orders in A-431 cells that express the human receptor due
to the favorable interaction with the side chains of Phe94
and Tyr174. Finally, Lys172 interacts with the nitrogen of
the pyridine ring of the ligand.
Anatibant
Previously known as LF 16-0687 (3 in Fig. 1), anatibant is
a potent B2 antagonist of Fournier with a IC50 of 0.67 nM
at the human receptor [23]. The compound shares the
8-benzyloxy-2-methyl-quinoline moiety with the two
antagonists described above, and in this case linked to a
pyrrolidine sulfonamide with a 4-amidinofenil moiety as
charged terminal group. Analysis of the different poses
found in our docking studies in view of the site-directed
mutagenesis results available suggest the molecule sits
inside the orthostheric site as shown in Fig. 7. As can be
seen the bound conformation of anatibant shows similari-
ties with that of fasitibant. Indeed, the common
8-dichlorobenzyloxy-2-methyl-quinoline substructure sits
in a similar manner inside the receptor. However the
stereochemical differences on the other side of the mole-
cules force them to exhibit differential poses as discussed
below.
The dichlorobenzyloxyl moiety of anatibant binds in the
same region of the receptor as fasitibant, consequently the
other moieties attached to it and shared between the two
molecules, including the quinoline and the sulfonamide,
access similar regions of the receptor. Specifically, the
sulfonyl groups exhibit hydrogen bonds with Asn107 and
Arg169, respectively. Moreover, the side chain of the latter
shows an additional hydrogen bond with one of the chlo-
rides of the dichlorophenoxyl moiety. On the other hand,
the quinoline moiety like in fastibant sits close to Tyr295
and interacts through a hydrogen bond and the quadrupole–
quadrupole interaction between the two aromatic rings.
Moreover, our docking studies also show the quinolone
moiety interacting with Ile110, Trp256 and Phe259. These
results are supported by mutagenesis studies, since the
mutation of Tyr295 to Phe295 reduces the affinity one order
of magnitude and to two orders of magnitude when
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mutated to Ala295 [39]. Similarly, the mutation of Trp256 to
Ala256 decreases the affinity one order of magnitude.
Moreover, this idea also explains the observed effect of the
mutation Asn297Ala in close contact with Trp256 [39].
Unfortunately there are no results available on the mutation
of Ile110 or Phe259 on the affinity of the ligand, but
Fig. 6 Pictorial view of the
proposed binding mode of
FR173657 to the BK B2
receptor
Fig. 7 Pictorial view of the
proposed binding mode of
anatibant to the BK B2 receptor
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according to the present modeling study it is expected one
order of magnitude decrease as shown in fasitibant [31]. On
the other side of the molecule anatibant and fasitibant
exhibit differential stereochemical features that force them
to bind in a differential way. This idea is supported by
mutagenesis studies, since the mutation of Asp266 or Asp284
to alanine decreases dramatically the binding affinity of
fasitibant but does not alter that of anatibant [36]. As it can
be seen in Fig. 7 the pyrrolidine ring sits perpendicular to
Trp86 interacting through a quadrupole–quadrupole inter-
action, being its position reinforced by a hydrogen bond
with the side chain of Arg169. The ring plays a fundamental
role in distributing the rest of the molecule and this justifies
the dramatic effect observed in the affinity of the com-
pound when the residue is mutated to alanine [40]. From
the pyrrolidine, the molecule extends towards the mouth of
the receptor with the aminoiminophenyl moiety surrounded
by polar residues including, Tyr174 of the second extra-
cellular loop or Gln22 located at the N-terminus. Moreover,
there are diverse polar residues that interact with the amide
groups of the molecule, including Glu24, Gln33 and Gln288.
The importance of the latter has been shown by mutagen-
esis studies [39].
WIN64338
This was the first non-peptide antagonist disclosed in the
literature with a Ki of 64 nM in human IMR90 fibroblasts
[20]. The antagonist was designed using a simple phar-
macophore defined by two charged groups separated by a
distance of about 10 A˚—mimicking the distance between
the two terminal arginines of BK in its bioactive confor-
mation- linked by lipophilic groups [20]. From a hit
obtained, subsequent medicinal chemistry efforts yielded
the compound WIN64338 (4 in Fig. 1). As can be seen the
compound exhibits two charged groups at both ends sur-
rounded by bulky hydrophobic groups, together with a
naphtyl moiety. The results of our docking study of the
compound onto the B2 receptor model is shown in Fig. 8.
WIN64338 is much shorter than the rest of the compounds
described so far and is consequently, expected to cover a
smaller region of the binding pocket. Although there are no
reports on directed mutagenesis studies conducted with the
compound, structure activity studies underline the impor-
tance of the two charges for high affinity. As can be seen,
the positively charged phosphine group nicely sits sur-
rounded by two negatively charged residues Asp266 and
Asp284, although the model suggest that is the latter that is
actually involved in a charge–charge interaction. In regard
to the dicyclohexylguanidinium moiety, of the bulky
cyclohexyl groups, one sits in the proximity of Trp86,
whereas the other points toward the solvent in a region
surrounded by Ala183 and Phe94 that provide a hydrophobic
environment. On the other hand, the charged nitrogen of
the guanidinium moiety exhibits a polar interaction with
the carbonyl oxygen of the Cys184 backbone. Finally, the
naphtyl group sits in the hydrophobic pocket in the prox-
imity of Trp256, Phe259 and Ile110, similarly as does the
quinoline moiety in the previous antagonists described
Bradyzide.
Bradyzide (5, in Fig. 1) is a potent, rat-selective B2
antagonist that causes a long lasting reversal of inflam-
matory hyperalgesia [22]. The compound is the result of a
lead optimization from a hit discovered by random
screening. Interestingly, the compound exhibits high
affinity for the rat B2 receptor (0.5 nM) expressed in
NG108-15 cell membranes, but much lower in human BK
B2 expressed in Cos-7 cells (772 nM). The result of the
docking study of this compound onto the BK B2 receptor is
shown in Fig. 9. There are no mutagenesis studies avail-
able that can help to understand the effect of diverse
mutations on the binding of bradyzide to the BK B2
receptor, but there is information about the effect of diverse
chemical substitutions on the molecule [41] that can be
analyzed through view of the complex model. Thus, the
terminal charged amino nitrogen located at the end of the
diaminoalkyl chain in bradyzide sits at the mouth of the
receptor, interacting with Asp266 in TM6 and Asp284 in
TM7, although the model actually suggests that is the latter
that is involved in a charge–charge interaction. Structure–
activity studies support this result by since elimination of
this chain decreases the affinity about 100 times [41].
Furthermore, these studies also point to the basicity of the
nitrogen as important feature to get better affinities, con-
firming the role of the terminal nitrogen in a charge–charge
interaction. In the model the sulfone group provides an
anchoring point to ligand through a hydrogen bond with
Gln33 in TM1. Further down the ligand, the aromatic ring
of the nitrobenzene moiety interacts with Trp86 in TM2
with the nitro group interacting with Asn107 via a hydrogen
bond. The sulfur of the thiosemicarbazyl moiety establishes
a hydrogen bond with Asn107 as has been previously sug-
gested and though a hydrophobic interaction with Ile110;
finally, the phenyl groups close to the thiosemicarbazyl
moiety sit well in the aromatic region Trp256, Phe259,
Tyr295.
CHEMBL442294
This compound (6, in Fig. 1) was the most active com-
pound of a series of benzodiazepines designed to mimic the
b–turn adopted by BK in its bioactive form [25]. This
peptidomimetic exhibits a binding affinity for the BK B2
receptor in the micromolar range, result that is consistent
with the low affinity exhibited by a series of cyclic peptides
designed to mimic the C-terminus of BK [13, 14]. These
94 J Comput Aided Mol Des (2016) 30:85–101
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results indicate that mimicking the C-terminus of the
peptide is necessary condition to get good binding affinity,
but not sufficient. Docking of the molecule into the
receptor generated diverse poses that were analyzed in
order to understand the features of the ligand-receptor
interaction. Figure 10 shows the ligand-receptor complex
Fig. 8 Pictorial view of the
proposed binding mode of
WIN64338 to the BK B2
receptor
Fig. 9 Pictorial view of the
proposed binding mode of
Bradyzide to the BK B2 receptor
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with the best docking score. As can be seen the ligand
adopts a pose covering a number of residues identified in
the docking in previous ligands. In this case, the guani-
dinium moiety binds to Asp284 and Gln288 in such a way
that allows the interaction of an aromatic ring with Trp86
and another with Trp256 and Phe259 in TM6. In addition, the
ligand exhibits a hydrogen bond between the carbonyl of
the diazepine ring and Arg169.
JSM10292
This compound (7, in Fig. 1) is the result of an optimiza-
tion process aimed to find low molecular mass non-peptide
B2 antagonists based on the structures of previously dis-
closed compounds [26]. Specifically, inspection of the
structure of diverse antagonist including FR173657 [21],
compound 8d [38], anatibant [23] and fasitibant [31] shows
that these molecules share a 8-benzyloxy-2-methyl-quino-
line as common structural feature. Thus, the authors used
this moiety as starting structure to follow a medicinal
chemistry approach, leading to the compound JSM10292
that exhibits an IC50 of 8.7 nM in the human BK B2
receptor, expressed in HEK293 cells [26]. Although the
molecule shares a common substructure with those mole-
cules used for its design, JSM10292 binds in different way.
Analysis of different poses obtained during the docking
process and analyzed according with the mutagenesis
results available [42], it was selected as putative bound
conformation the one shown in Fig. 11. Indeed, the pyra-
zole substituent to the quinoline group sits close to Phe259
with one of the pyrazole nitrogens acting as proton
acceptor in a hydrogen bond interaction with Thr263.
Although there are not mutagenesis results on the role of
the latter, the results underline the important role of Phe259
acting as anchoring point of the bound conformation. The
nitrogen of the quinolone ring and the oxygen atom of the
benzyloxy moiety interact via a hydrogen bond with
Tyr295; the nitrogen of the pyridine interacts with the side
chain of Arg169, whereas the aromatic ring and its methyl
group sit close to Ile110; the carbonyl oxygen of the tri-
fluoropyridone moiety also interacts with Arg169 and the
pyridone ring interacts with Trp86 whereas the tri-
fluromethyl group interacts with Asn107.
The bound conformation of JSM10292 found in the
present study differs slightly of the one described in ref-
erence 40. The two models actually differ in the confor-
mation of the ligands. In our model the ligand gets an
extended conformation, whereas in their model the ligand
adopts a conformation the trifluoropyridone ring folds back
towards the pyridine ring. As result of the different con-
formation, the trifluromoiety interacts in the present model
with Asn107 whereas in the other model gets close to
Ser111. In fact, there are not mutagenesis results of the
mutation of serine to alanine; however the replacement to
lysine provokes a great loss of affinity [42]. However, due
to the size of the lysine side chain in both models a steric
Fig. 10 Pictorial view of the
proposed binding mode of
CHEMBL442294 to the BK B2
receptor
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hindrance is generated to perturb the binding of the ligand
and consequently does not allow discriminating between
the two models.
Comparison of the complex ligand-receptor of the dif-
ferent antagonists used for the present study suggests the
definition of a pharmacophore that explains the observed
structure–activity. It consists of five pharmacophoric points
that not all the ligands studied in the present study fulfill.
The pharmacophore proposed is shown in Fig. 12 and it is
defined considering geometrical constraints on ligand
moieties. Thus, point 1 is a proton donor center that will
interact with Asp84 and/or Asp266; point 2 is either a proton
accepting/proton donor center that will interact with either
Gln32 or Gln288; point 3 is a hydrophobic ring that will
interact with Trp86; point 4 is a proton accepting center that
will interact with Asn107 and/or Arg169; point 5 is a
hydrophobic/aromatic site that will interact with Trp256,
Phe259 and Tyr295.
Thus, fasitibant fulfils point 1 by means of the terminal
amine; point 3 by means of the dichlorophenoxyl moiety;
point 4 by means of one of the sulfonyl oxygens as well as
one of the chlorines and point 5 by means of the quinoline
moiety. In the case of FR173657 point 2 is fulfilled by
means of one of the amide groups; point 3 is fulfilled by
means of the dichlorophenoxyl moiety that also fulfills
point 4 by means of one of the chlorine atoms; point 5 is
fulfilled by means of the quinoline moiety. In the case of
anatibant point 2 is fulfilled by means of the pyrrodiline
amide; point 3 by means of the pyrrolidine ring; point 4 by
means of the sulfonyl groups and point 5 by means of the
quinoline moiety. In the case of WIN64338 point 1 of the
pharmacophore is fulfilled by the phosphine group; point 3
Fig. 11 Pictorial view of the
proposed binding mode of
JSM10292 to the BK B2
receptor
Fig. 12 Proposed pharmacophore for the BK B2 antagonism.
Distance between pharmacophoric points are: d(1,2) = 8.8 A;
d(1,3) = 17.4; d(1,4) = 15.5; d(1,5) = 12.2; d(2,3) = 12.1; d(2,4) =
12.2; d(2,5) = 11.6; d(3,4) = 7.2; d(3,5) = 8.8; d(4,5) = 10.3
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is fulfilled by one of the cyclohexanes; point 4 by the amide
carbonyl and point 5 by means of the naphtyl moiety. In
bradyzide point 1 is fulfilled by the terminal amine; point 2
is fulfilled by one of the sulphonyl oxygens, although in
this case the interaction is more likely with Gln33 in the
vicinity of Gln288; point 3 is fulfilled by means of the
nitrobenzene moiety and point 5 by means of the phenyl
terminal groups. For CHEMBL442294 point 1 is fulfilled
by the guanidinium moiety; point 3 by means of the phenyl
substituent of the benzodiazepine scaffold and point 5 by
means of the bezyl moiety. In the case of JSM10292 point
1 is fulfilled by means of the pyrazole moiety; point 3 is
fulfilled by means of the pyrazone moiety that also fulfils
point 4 by means of the carbonyl group. Finally, point 5 is
fulfilled by means of the quinoline moiety.
Present pharmacophore includes others previously
described in the literature. Specifically, the simple phar-
macophore proposed by Salvino et al. [43] consisting in
Table 1 Structures of the new
hits discovered in this work
Their antagonistic potency towards the human B2 bradykinin receptor and the number of pharmacophore
points fulfilled is also shown
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two charges separated 10 A˚ that gave rise to the discovery
of WIN64338, includes points 1 and 4 of the present
pharmacophore. On the other hand, in order to mimic the
C-terminus of BK after a thorough exploration of the
conformational space of the five bradykinin analogues, it
was suggested a few years ago a partial pharmacophore for
BK antagonism [44, 45]. This includes an ionizable posi-
tive charge, a hydrophobic group and an aromatic/hy-
drophobic group in a specific spatial arrangement of
4.5–7.5, 5.5–8–5 and 8.5 A˚. This pharmacophore is
included in the more general pharmacophore described in
the present work. Distances are not directly comparable
since in the present pharmacophore distances are defined
on the side chains of receptor residues and not on the
chemical moieties. Thus, the ionizable positive charge is
the moiety facing point 2 of the present pharmacophore;
the hydrophobic group is the one facing point 5 of the
present pharnacophore and the aromatic ring is the moiety
interacting with point 3 in the present pharmacophore.
Proof of concept
We used the pharmacophore described above for the dis-
covery of new structures with antagonistic activity for the
B2 bradykinin receptor by virtual screening. For this pur-
pose we searched for compounds fulfilling at least three
pharmacophore points in different data bases of 3D struc-
tures of compounds including, the Available Chemical
Directory (ACD), the Derwent World Drug Index, the
National Cancer Institute (NCI) and Maybridge for a total
of approximately 500,000 compounds. The search yielded
a set of compounds that were subsequently classified into a
few clusters. Specifically, molecules were first encoded
into vectors using the fulfillment of three-point pharma-
cophores as criterion; second, a distance between vectors
was computed using the Tanimoto index and, third a
hierarchical clustering algorithm was used to classify the
molecules [46]. A representative member of each of the
clusters if available was purchased and tested for their B2
antagonistic activity.
Biological assays permitted to identify new hits with
structures that do not resemble those used for pharma-
cophore development. The success rate was approximately
one-third of the molecules tested as previously found by
other authors in similar studies [47]. Table 1 shows the
structures as well as the antagonistic activity to the human
bradykinin B2 receptor of a selected group of hits, dis-
closed to give support to the pharmacophore hypothesis
developed in this work. These molecules were docked onto
the receptor model and inspected for fulfillment of the
pharmacophore. Information regarding the number of
pharmacophore points fulfilled by each of the hits is also
included in Fig. 11. As an example, Fig. 13 shows the
proposed binding mode of compound (8) to the B2 recep-
tor, showing the fulfillment of the pharmacophoric points.
Interestingly, the antagonistic activity observed
Fig. 13 Pictorial view of the
proposed binding mode of
compound (8) (see Table 1) to
the BK B2 receptor with the
pharmacophore points
represented as spheres of
different colors: cyan for a
proton donor/positive charge;
magenta for a proton
acceptor/donor; yellow for an
hydrophobic ring; dark green
for an aromatic/hydrophobic
moiety
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experimentally correlates well with the number of phar-
macophoric points fulfilled by these molecules.
Conclusions
We have constructed models of the bound conformation of
diverse non-peptide B2 bradykinin antagonist and analyzed
the stereochemical features of the complexes with the aim to
find common trends. For this purpose we first constructed an
atomistic model of the receptor by homologymodeling, using
the CXC4 chemokine receptor as template. Antagonists
selected for the present study include fasitibant, FR173657,
anatibant, WIN64338, bradyzide, CHEMBL442294 and
JSM10292, encompassing the maximum possible diversity.
Complexes with the bound conformation of each of the
antagonists were constructed by docking the molecules into
the receptor. Due to the flexibility of the ligands and the size of
the orthosteric site of the receptor, several docking attempts
were carried out for each of the molecules. The final confor-
mation was selected by the scoring function and the results on
site directed mutagenesis studies available.
Our results suggest that there are certain anchoring points
that are found in more than one compound permitting the
definition of a common pharmacophore. This consist of five
points that defined on the features of the ligand include a
proton donor/positive charge (point 1), a proton acceptor/
proton donor (point 2), an aromatic/planar hydrophobic
moiety (point 3), a proton acceptor/proton donor (point 4)
and a hydrophobic/aromatic moiety (point 5).
The pharmacophore was used in a subsequent study to
guide a virtual screening process. The results permitted to
identify a set of compounds some of which were purchased
and in vitro tested for their capability to antagonize the
bradykinin B2 receptor. In the present work we disclose a
subset of these compounds that give support to the validity
of the pharmacophoric hypothesis described in this work.
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